Pathology & Clinical Laboratory (M) Sdn., a Southeast Asian medical testing company, is considering selling its business in Malaysia which could fetch about $200 million in a transaction, according to people with knowledge of the matter.
Pathlab, as the company is known, is working with an adviser on the potential divestment, the people said. While the sale process hasn’t formally started, some buyout firms and hospital operators have expressed initial interest, said the people, who asked not to be identified as the information is private.
